Bomedemstat for Essential Thrombocythemia

"The ongoing trial is being conducted in 7 different medical centres, including Ann Arbor, Durham and Jacksonville. To reduce travel time and costs, it is best to pick the most convenient clinic for you if you plan on enrolling."

"IMG-7289 has been investigated since 2020, when the original study sponsored by Imago BioSciences Inc. was launched with an enrollment of 20 participants. After receiving Phase 2 drug approval following its initial exploration in 2020, there are now 4 current experiments for IMG-7289 taking place across 7 different countries and 15 cities globally."

"Currently, four active clinical trials are evaluating the effects of IMG-7289 with none in Phase 3. A multitude of medical centres located in Jena and Victoria are running these studies while 28 other sites worldwide have launched investigations into the efficacy of this drug."

"At this moment, recruitment for the trial has paused. This medical study was first added to clinicaltrials.gov on September 20th 2020, and subsequently updated on April 15th 2022; however, if you are searching for alternatives there are 51 trials involving thrombocythemia essential, as well as 4 studies focusing on IMG-7289 that have begun admitting patients."

"IMG-7289 has been evaluated as a level 2 on our safety scale; this Phase 2 trial provides evidence of its security, but there are no published studies validating its efficacy."

"At this moment, patient recruitment has been paused for this clinical trial. The study was initially made available to the public on September 20th 2020 and its details were last edited April 15th 2022. Individuals looking for additional studies may find 51 trials actively enrolling patients with thrombocythemia or essential IMG-7289 is being studied in four separate medical investigations which are currently open to enrollment."